Glenmark Pharmaceuticals has received final USFDA approval for Pimecrolimus cream Kumar Jeetendra | September 1, 2019 Glenmark Pharmaceuticals,has received final approval from the USFDA for Pimecrolimus cream, used to treat skin conditions such as eczema. The approved product is a generic version of Elidel cream 1 per cent, of Bausch Health US, LLC. Citing IQVIA sales data, Glenmark said, Elidel cream achieved annual sales of approximately $198.8 million in the 12-month …
Instrument Training eLearning Platform launched by Micromeritics Instrument Corp Kumar Jeetendra | August 26, 2019 Micromeritics Instrument Corp. a USA based company mainly engaged in the manufacturing of premium products for advanced material characterization has announced the launch of its Micromeritics Learning Center (MLC)v Online Instrument Training eLearning Platform. The courses are: AccuPyc II 1340 (PC and Keypad), GeoPyc 1365 (Envelope and T.A.P. Density), and MIC SAS 5800. The platform …
Alvotech and Cipla gulf enter into a partnership for the commercialization of key biosimilar in select emerging markets Kumar Jeetendra | July 29, 2019 Reykjavik, Iceland & Mumbai, India; 29 July 2019 – Biopharmaceutical company Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as “Cipla”), today announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the …
InvaGen a Cipla subsidiary receives final approval for generic version of Pfizers Lyrica Kumar Jeetendra | July 22, 2019 Central Islip, New York, USA & Mumbai, India; July 22, 2019: – InvaGen Pharmaceuticals, Inc. (“InvaGen”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla") announced the receipt of final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, …
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China Kumar Jeetendra | June 28, 2019 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A …
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China Kumar Jeetendra | June 28, 2019 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A …
Sun Pharma and China Medical System Holdings enter into a License Agreement for Cyclosporine A eye drops in Greater China Kumar Jeetendra | June 28, 2019 Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that one of its wholly owned subsidiaries has entered into an exclusive licensing agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for the development and commercialization of Cyclosporine A …
Indias Biggest Pharma Expo in the National Capital Kumar Jeetendra | June 15, 2019 Indian Pharma Expo 2019 is coming up on 16th, 17th & 18th July at Hall 12A Pragati Maidan, New Delhi. New Delhi: India’s famous Pharma event “Indian Pharma Expo 2019” will be inaugurated on 16th July at HALL No. 12A, Pragati Maidan, New Delhi. At the time of inauguration Key dignitaries from Department of Pharmaceuticals, …
Dr Reddys Laboratories announces the relaunch of Zenatane in the US Market Kumar Jeetendra | June 3, 2019 Hyderabad, India and Princeton, NJ, USA. June 3, 2019 — Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg a therapeutic equivalent generic version of Accutane®, …
Cipla receives final approval for generic version of Gilead Sciences Incs Letairis AmbrisentanTabs 5mg and 10mg Kumar Jeetendra | April 30, 2019 Mumbai, India; April 30, 2019: – Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce receipt of final approval for the Abbreviated New Drug Application (ANDA) for Ambrisentan Tablets 5mg & 10mg from the United States Food and Drug Administration (US FDA). rnrn rn Cipla’s Ambrisentan Tablets 5mg & 10mg …
Lupin in alliance with Natco receives FDA approval for Bosentan Tablets Kumar Jeetendra | April 30, 2019 Mumbai, Baltimore, April 30, 2019: Lupin Limited (Lupin) in alliance with Natco Pharma (Natco) announced that it has received approval for Bosentan Tablets, 62.5 mg and 125 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Actelion Pharmaceuticals Limited’s Tracleer Tablets, 62.5 mg and 125 mg. rnrn Lupin …
Cipla appoints Dr Raju Mistry as Global Chief People Officer Kumar Jeetendra | April 22, 2019 Mumbai, April 22, 2019 – Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announces the appointment of Dr. Raju Mistry as President and Global Chief People Officer (GCPO) of Cipla. Raju is an accomplished and veteran Human Resources (HR) leader with over 27 years of global experience across diverse sectors …
